Literature DB >> 24575895

Vaccines for Pseudomonas aeruginosa: a long and winding road.

Gregory P Priebe1, Joanna B Goldberg.   

Abstract

Despite the recognition of Pseudomonas aeruginosa as an opportunistic pathogen, no vaccine against this bacteria has come to market. This review describes the current state-of-the-art in vaccinology for this bacterium. This includes a discussion of those at risk for infection, the types of vaccines and the approaches for empirical and targeted antigen selection under development, as well as a perspective on where the field should go. In addition, the challenges in developing a vaccine for those individuals at risk are discussed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24575895      PMCID: PMC4521563          DOI: 10.1586/14760584.2014.890053

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  144 in total

1.  Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection.

Authors:  Kyle I Happel; Mingquan Zheng; Erana Young; Lee J Quinton; Euan Lockhart; Alistair J Ramsay; Judd E Shellito; Jill R Schurr; Gregory J Bagby; Steve Nelson; Jay K Kolls
Journal:  J Immunol       Date:  2003-05-01       Impact factor: 5.422

Review 2.  Update in cystic fibrosis 2012.

Authors:  Christopher H Goss; Felix Ratjen
Journal:  Am J Respir Crit Care Med       Date:  2013-05-01       Impact factor: 21.405

3.  Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection.

Authors:  Carlos E Milla; James F Chmiel; Frank J Accurso; Donald R VanDevanter; Michael W Konstan; Geoffrey Yarranton; David E Geller
Journal:  Pediatr Pulmonol       Date:  2013-09-09

4.  IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis.

Authors:  Yutaka Komiyama; Susumu Nakae; Taizo Matsuki; Aya Nambu; Harumichi Ishigame; Shigeru Kakuta; Katsuko Sudo; Yoichiro Iwakura
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

5.  Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis.

Authors:  S Hemachandra; K Kamboj; J Copfer; G Pier; L L Green; J R Schreiber
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

Review 6.  Polysaccharide antigens of Pseudomonas aeruginosa.

Authors:  Y A Knirel
Journal:  Crit Rev Microbiol       Date:  1990       Impact factor: 7.624

Review 7.  Burn wound infections.

Authors:  Deirdre Church; Sameer Elsayed; Owen Reid; Brent Winston; Robert Lindsay
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

Review 8.  Diagnosis and management of infectious complications in critically ill patients with cancer.

Authors:  Raghukumar Thirumala; Madhusudanan Ramaswamy; Sanjay Chawla
Journal:  Crit Care Clin       Date:  2010-01       Impact factor: 3.598

9.  Protection of immunocompromised mice against lethal infection with Pseudomonas aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins.

Authors:  B U von Specht; B Knapp; G Muth; M Bröker; K D Hungerer; K D Diehl; K Massarrat; A Seemann; H Domdey
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

10.  Epitope mapping of monoclonal antibodies using synthetic oligosaccharides uncovers novel aspects of immune recognition of the Psl exopolysaccharide of Pseudomonas aeruginosa.

Authors:  Huiqing Li; Kai-For Mo; Qun Wang; C Kendall Stover; Antonio DiGiandomenico; Geert-Jan Boons
Journal:  Chemistry       Date:  2013-11-18       Impact factor: 5.236

View more
  42 in total

Review 1.  Innate Immune Signaling Activated by MDR Bacteria in the Airway.

Authors:  Dane Parker; Danielle Ahn; Taylor Cohen; Alice Prince
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

2.  Immunological considerations in the development of Pseudomonas aeruginosa vaccines.

Authors:  Sarah M Baker; James B McLachlan; Lisa A Morici
Journal:  Hum Vaccin Immunother       Date:  2019-09-05       Impact factor: 3.452

3.  Retargeting pre-existing human antibodies to a bacterial pathogen with an alpha-Gal conjugated aptamer.

Authors:  Sascha A Kristian; John H Hwang; Bradley Hall; Emma Leire; John Iacomini; Robert Old; Uri Galili; Charles Roberts; Kary B Mullis; Mike Westby; Victor Nizet
Journal:  J Mol Med (Berl)       Date:  2015-05-05       Impact factor: 4.599

4.  Post-exposure immunization by capsid-modified AdC7 vector expressing Pseudomonas aeruginosa OprF clears P. aeruginosa respiratory infection.

Authors:  Rika Gomi; Anurag Sharma; Wenzhu Wu; Biin Sung; Stefan Worgall
Journal:  Vaccine       Date:  2017-11-07       Impact factor: 3.641

5.  Multiantigenic Nanotoxoids for Antivirulence Vaccination against Antibiotic-Resistant Gram-Negative Bacteria.

Authors:  Xiaoli Wei; Danni Ran; Anaamika Campeau; Crystal Xiao; Jiarong Zhou; Diana Dehaini; Yao Jiang; Ashley V Kroll; Qiangzhe Zhang; Weiwei Gao; David J Gonzalez; Ronnie H Fang; Liangfang Zhang
Journal:  Nano Lett       Date:  2019-06-11       Impact factor: 11.189

Review 6.  Antibody-Dependent Enhancement of Bacterial Disease: Prevalence, Mechanisms, and Treatment.

Authors:  Von Vergel L Torres; Carrie F Coggon; Timothy J Wells
Journal:  Infect Immun       Date:  2021-03-17       Impact factor: 3.441

7.  A facile approach for development of a vaccine made of bacterial double-layered membrane vesicles (DMVs).

Authors:  Sihan Wang; Jin Gao; Mo Li; Liguo Wang; Zhenjia Wang
Journal:  Biomaterials       Date:  2018-10-01       Impact factor: 12.479

8.  Quest for Novel Preventive and Therapeutic Options Against Multidrug-Resistant Pseudomonas aeruginosa.

Authors:  Sidra Irum; Saadia Andleeb; Amjad Ali; Muhammad Ibrahim Rashid; Mahnoor Majid
Journal:  Int J Pept Res Ther       Date:  2021-08-09       Impact factor: 1.931

Review 9.  Leveraging Pseudomonas Stress Response Mechanisms for Industrial Applications.

Authors:  Kelly Craig; Brant R Johnson; Amy Grunden
Journal:  Front Microbiol       Date:  2021-05-10       Impact factor: 5.640

Review 10.  Immunization and Immunotherapy Approaches against Pseudomonas aeruginosa and Burkholderia cepacia Complex Infections.

Authors:  Sílvia A Sousa; António M M Seixas; Joana M M Marques; Jorge H Leitão
Journal:  Vaccines (Basel)       Date:  2021-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.